about
Activation of rapid oestrogen signalling in aggressive human breast cancersRadiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor typeXenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cellsTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerSteroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancerIntroducing a new section to Breast Cancer Research: endocrinology and hormone therapyDrugging the undruggables: exploring the ubiquitin system for drug developmentDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerIdentifying and targeting tumor-initiating cells in the treatment of breast cancerCooperating transcription factors mediate the function of estrogen receptorHuman mammaglobin in breast cancer: a brief review of its clinical utilityModulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cellsGrowth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathwayDeregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumorsFulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexThe role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.Estrogen action: a historic perspective on the implications of considering alternative approaches.VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley ratsZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.Discovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency.Estrogen-mediated epigenetic repression of large chromosomal regions through DNA loopingClassical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Function of RasGRP3 in the formation and progression of human breast cancerDifferential Shannon entropy and differential coefficient of variation: alternatives and augmentations to differential expression in the search for disease-related genes.Binding of the ERalpha nuclear receptor to DNA is coupled to proton uptake.Chromatin remodeling in mammary gland differentiation and breast tumorigenesis.Estrogen-mediated effects on cognition and synaptic plasticity: what do estrogen receptor knockout models tell us?Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.Nuclear hormone receptors in parasitic helminths.The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulatorsAcquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsCo-ordination of cell cycle, migration and stem cell-like activity in breast cancer.Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.Expression and prognostic value of estrogen receptor beta in breast cancer patients.Genetic variations within the ERE motif modulate plasticity and energetics of binding of DNA to the ERα nuclear receptor.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancerCatechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells.The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
P2860
Q24300885-56A4AA2C-75F5-43C5-98E1-E7365BA4ACAFQ24620175-A8A4F3CD-8E3B-4899-8001-5E3DED0B2A44Q24634687-3BE19DBB-6C51-4048-A9E7-6380D786AB90Q24670339-1E2260EC-ACAA-4308-A042-875E9FDD7893Q24680310-655707DC-9D49-4921-B83A-3647ACAA94B7Q24802767-08C3296F-B0AB-4B83-BB14-B6D9BCFF18A9Q26752823-072A4DA8-CF99-4CEB-BC3E-B0FC9C2FCEC1Q26825584-95091ACC-A339-45AB-89CB-30C082F39256Q26851827-D2826FB3-9558-400F-A4D3-F5DFC535B5EDQ26996464-B1F90136-E97B-46BA-A4C7-9ECF29EB8655Q27001274-535A6EC2-F63D-47BF-8078-787D4E9F60F7Q28261025-C7CC3850-E0F2-45BD-88BD-B807601BA5FFQ28281599-C778BA1E-7B1E-4FDF-BD8E-5ADBF41928FAQ28296627-6AB1F404-55EB-4B89-87CC-EA5AF458F4A6Q28301066-EE12F267-138E-4D17-B5F6-F0BADD8FA426Q30432909-19FCE95B-8764-480E-A80A-F4611149EA0FQ33709986-C093B69E-A7A6-4D27-9E9F-5836F424F3ABQ33717781-4FC3E7B4-AA55-490D-8621-82BB8A8598E5Q33815885-7F57D529-926C-4064-9F4B-A7764A50EACEQ33834493-C979FE5F-740C-44B8-BFBE-BB2EAC807EE6Q33881333-7AD0F517-07F3-443C-A139-247F980E3195Q33903965-2C0D4970-A680-4206-B706-4F83B0F47C74Q33960160-F24DF101-5000-42B7-BFE9-E3687EF2DFDCQ34020239-D7519042-1761-4CAD-970F-DD543EACCF4EQ34029522-77281987-E888-4012-AD9B-CDB7236C307FQ34080232-34E1EADC-4286-4802-A6E6-A6470DEFEBE5Q34170306-C5E5F2B6-C98E-4728-A89D-C2C4D88FE486Q34193867-99488A80-9639-4966-96E1-887CB0BA6BA3Q34283432-596A831B-9169-4BC8-8EDA-E1F48AA0E553Q34315816-45ED2C81-061D-4DA4-BF5D-A3DDB8C9E018Q34315889-5D361016-E4D5-4DB3-A74F-D60FFC86FE48Q34365904-A98AA4B4-B3A3-4B19-9A72-79AF88130F43Q34411166-20F85E47-5807-4710-9639-977783842116Q34547653-8BC12525-007F-45A3-B527-1F33331751F4Q34605907-8E442D53-0105-47B7-8FCA-A278B583BA1DQ34736075-8568EFB8-7AD7-45D8-A956-1E3CF30AB73EQ35023715-CD5CC183-3475-405D-8F49-7FD6AFC752C3Q35062498-9939DE6B-11B5-45F0-BE8A-7121C1311E8DQ35144535-B1D2849B-A807-406C-8DE5-F82BAF802840Q35191588-19582375-8471-48C0-BB50-A8443A73F70A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The estrogen receptor: a model for molecular medicine.
@ast
The estrogen receptor: a model for molecular medicine.
@en
The estrogen receptor: a model for molecular medicine.
@nl
type
label
The estrogen receptor: a model for molecular medicine.
@ast
The estrogen receptor: a model for molecular medicine.
@en
The estrogen receptor: a model for molecular medicine.
@nl
prefLabel
The estrogen receptor: a model for molecular medicine.
@ast
The estrogen receptor: a model for molecular medicine.
@en
The estrogen receptor: a model for molecular medicine.
@nl
P1476
The estrogen receptor: a model for molecular medicine
@en
P2093
Elwood V Jensen
V Craig Jordan
P304
P407
P577
2003-06-01T00:00:00Z